Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Atypical Teratoid/Rhabdoid Tumor.
- Author:
Ki Woong SUNG
1
;
Do Hoon LIM
;
Eun Sang YI
;
Young Bae CHOI
;
Ji Won LEE
;
Keon Hee YOO
;
Hong Hoe KOO
;
Ji Hye KIM
;
Yeon Lim SUH
;
Yoo Sook JOUNG
;
Hyung Jin SHIN
Author Information
- Publication Type:Original Article
- Keywords: Brain neoplasms; Chemotherapy; Hematopoietic stem cell transplantation; Radiotherapy
- MeSH: Brain Neoplasms; Child; Diagnosis; Disease Progression; Drug Therapy*; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Prospective Studies; Radiotherapy; Recurrence; Salvage Therapy; Stem Cell Transplantation*; Stem Cells*
- From:Cancer Research and Treatment 2016;48(4):1408-1419
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: We prospectively evaluated the effectiveness of tandem high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT) in improving the survival of patients with atypical teratoid/rhabdoid tumors while reducing the risks of late adverse effects from radiotherapy (RT). MATERIALS AND METHODS: For young children (< 3 years old), tandem HDCT/auto-SCT was administered after six cycles of induction chemotherapy. RT was deferred until after 3 years of age unless the tumor showed relapse or progression. For older patients (> 3 years old), RT including reduced-dose craniospinal RT (23.4 or 30.6 Gy) was administered either after two cycles of induction chemotherapy or after surgery, and tandem HDCT/auto-SCT was administered after six cycles of induction chemotherapy. RESULTS: A total of 13 patients (five young and eight older) were enrolled from November 2004 to June 2012. Eight patients, including all five young patients, had metastatic disease at diagnosis. Six patients (four young and two older) experienced progression before initiation of RT, and seven were able to proceed to HDCT/auto-SCT without progression during induction treatment. Three of six patients who experienced progression during induction treatment underwent HDCT/auto-SCT as salvage treatment. All five young patients died from disease progression. However, four of the eight older patients remain progression-freewith a median follow-up period of 64 months (range, 39 to 108 months). Treatment-related late toxicities were acceptable. CONCLUSION: The required dose of craniospinal RT might be reduced in older patients if the intensity of chemotherapy is increased. However, early administration of RT should be considered to prevent early progression in young patients.
